In the third episode of Onyx Newsroom’s JPM 2026 interview series, Max Baumann, Partner at Treehill Partners, addressed one of the most fundamental questions facing the industry: will biotech remain relevant as a sector by 2030?
The conversation probes how large pharma’s increasingly sophisticated deployment of AI into drug discovery may fundamentally reshape biotech’s role and business model. If pharma can access innovative molecules more directly — bypassing the traditional biotech innovation engine — the implications for how small companies are built, funded, and valued are profound. Max also addressed whether Europe has missed the strategic window created by recent US market uncertainty, and how companies can prepare for therapeutic commercialisation under shifting government priorities and regulatory frameworks.
Treehill’s JPM 2026 programme included a series of closed-door roundtables on the industry’s most pressing strategic topics. The Onyx interview series gave that intelligence a wider audience.
Watch the full interview: https://www.onyxnewsroom.com/will-biotech-still-be-relevant-in-2030-treehill-partners-ep-3-jpm-2026/
📌 Treehill Partners – helping biopharma companies optimize development strategies for both regulatory approval and commercial success, unlocking transaction optionality with strategic and financial players.